Old news see original link here
plus from The Australian this morning
ResMed cut to Underperform from Neutral at Macquarie.
Noting SERVE HF, the largest randomised study ever examining survival for PAP therapy, Macquarie said that it believes the study will impact prescribing behaviour more broadly than its direct study population.
“We also see risk that the large upcoming studies examining CPAP outcomes may not deliver the positive results we believe the market has baked-in,” the broker said.
Would take their comments as a grain of salt.
Old news see original link here plus from The Australian this...
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RMD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$38.11 |
Change
-0.240(0.63%) |
Mkt cap ! $22.38B | |||
| Open | High | Low | Value | Volume |
| $38.50 | $38.57 | $37.66 | $49.01M | 1.287M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 6322 | $38.11 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $38.12 | 8095 | 3 |
View Market Depth
| Last trade - 16.10pm 27/11/2024 (20 minute delay) ? |
| RMD (ASX) Chart |
